On August 21, 2026, the congressional push to decouple U.S. biotechnology and drug development from the People's Republic of China (PRC) escalated from active pharmaceutical ingredient (API) supply chains into the core evidence generation machinery of modern biopharma.
As first reported by Endpoints News and confirmed by BioSpace, Representative John Moolenaar (R-MI), Chairman of the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party (CCP), alongside Representative Ben Cline (R-VA), sent a formal oversight letter to Acting FDA Commissioner Kyle Diamantas.
The lawmakers issued two direct, consequential demands to the agency:
- Institute an Immediate Audit Gate: Reject clinical trial data generated in China for U.S. drug and biologic applications unless the specific trial site has undergone a recent, rigorous on-site inspection by FDA's Bioresearch Monitoring (BIMO) program; and
- Launch a Retroactive Product Review: Conduct a comprehensive regulatory reassessment of all therapeutics already approved for the U.S. market whose pivotal approval packages relied on China-based clinical trial data.
Coming on the heels of three highly publicized patient fatalities in China-based investigator-initiated gene and cell therapy trials disclosed between late July and August 2026, the letter signals a decisive shift in congressional pressure.
For regulatory affairs directors, chief medical officers, and pipeline strategy leads who have integrated Chinese clinical sites into their global development programs to accelerate patient enrollment and reduce trial costs, what would an FDA audit condition actually mean, how does it fit into the broader legislative timeline, and what should sponsors do today?
The congressional demand: Two asks and their operational meaning
To evaluate the operational exposure for biopharma pipelines, regulatory teams must parse the specific mechanisms requested by lawmakers:
┌─────────────────────────────────────────────────────────────────────────────────────────────┐
│ THE MOOLENAAR-CLINE CONGRESSIONAL OVERSIGHT LETTER │
├──────────────────────┬──────────────────────────────────────────────────────────────────────┤
│ Letter Metadata │ August 21, 2026 • House Select Committee on the CCP │
│ Signatories & Target │ Rep. John Moolenaar (R-MI) & Rep. Ben Cline (R-VA) to Acting FDA │
│ │ Commissioner Kyle Diamantas │
├──────────────────────┼──────────────────────────────────────────────────────────────────────┤
│ Primary Demand #1: │ PROSPECTIVE AUDIT GATE │
│ Prospective Policy │ Reject clinical study data generated at trial sites in the PRC │
│ │ unless the specific site has been recently audited on-site by FDA. │
├──────────────────────┼──────────────────────────────────────────────────────────────────────┤
│ Primary Demand #2: │ RETROACTIVE APPROVAL AUDIT │
│ Retrospective Review │ Initiate a formal regulatory review of all approved NDAs and BLAs │
│ │ whose licensing packages relied on China-based pivotal study data. │
├──────────────────────┼──────────────────────────────────────────────────────────────────────┤
│ Immediate Trigger │ Disclosures of three patient fatalities in China-based gene and cell │
│ │ therapy investigator-initiated trials (IITs), July–August 2026. │
├──────────────────────┼──────────────────────────────────────────────────────────────────────┤
│ Operational Impact │ If adopted, functions as a de facto moratorium on China trial data │
│ If Enacted │ due to severe FDA foreign BIMO inspection backlogs and travel caps. │
└──────────────────────┴──────────────────────────────────────────────────────────────────────┘
ESCALATION TRACK OF CONGRESSIONAL SCRUTINY OVER CHINA TRIAL DATA
AUG 2024 ──► Bipartisan Select Committee Letter to FDA
Investigates US pharma clinical trials at PLA military hospitals.
APR-MAY ──► FY 2027 House Agriculture-FDA Appropriations
2026 Report language directs FDA to bar acceptance of
covered-nation (incl. China) site data at IND stage.
JUN 2026 ──► Oversight Letters to 5 Pharma CEOs
Pfizer, AbbVie, Lilly, Merck, BMS cited for China site exposure.
AUG 2026 ──► Three Disclosed Gene/Cell Therapy Deaths in China
HuidaGene CRISPR death, Nature omission case, CAR-T fatality.
AUG 2026 ──► Moolenaar-Cline Letter Demands Prospective Audit Gate & Retroactive Review
The documentary escalation: From military hospitals to appropriations riders
The August 21 letter does not represent an isolated congressional inquiry; it is the culmination of a meticulously documented, multi-year oversight campaign spearheaded by the House Select Committee on the CCP.
1. August 20, 2024: The Initial Bipartisan FDA Inquiry
Two years prior, Chairman Moolenaar and Ranking Member Raja Krishnamoorthi (D-IL) — joined by Reps. Neal Dunn (R-FL) and Anna Eshoo (D-CA) — sent a bipartisan letter to FDA requesting an investigation into U.S. pharmaceutical companies conducting clinical research in collaboration with PRC military entities (People's Liberation Army hospitals) and in the Xinjiang Uyghur Autonomous Region. The committee emphasized the national security risks of dual-use biosecurity research and intellectual property transfer.
2. March 18, 2026: Congressional Hearing on Medicine Supply Chains
During a full committee hearing formally titled "From the Science Lab to the Medicine Cabinet: How China is Cornering the Market on Our Medicines", Chairman Moolenaar criticized FDA's historical practice of accepting foreign clinical data without routine, mandatory pre-approval site inspections, arguing that regulatory reliance on uninspected overseas facilities created profound data integrity and patient safety blind spots.
3. Late April 2026: The FY 2027 Appropriations Report Language
In late April 2026, the House Appropriations Committee advanced FY 2027 Agriculture-FDA funding legislation whose accompanying report language — championed by Moolenaar, a member of the subcommittee — directed FDA to bar the acceptance, review, or consideration of covered clinical data generated at investigation sites located in covered nations (China, Russia, Iran, and North Korea, as defined at 10 U.S.C. 4872(f)) in support of IND applications. That language sits in committee report text, which guides but does not itself carry the force of enacted statute; the House passed the underlying bill in June 2026.
4. June 30, 2026: Letters to Five Major Pharma CEOs
On June 30, 2026, the Select Committee escalated pressure directly onto commercial sponsors, sending individualized oversight letters to the Chief Executive Officers of Pfizer, AbbVie, Eli Lilly, Merck, and Bristol Myers Squibb. Drawing from staff analyses of public clinical trial registry data, the letters asserted significant trial exposure:
- Pfizer: Asserted by the committee to have conducted at least 43 trials involving PRC military-affiliated hospitals and at least 6 trials in Xinjiang.
- AbbVie: Asserted to have conducted at least 16 trials involving military hospitals and at least 17 trials in Xinjiang.
For parallel analysis of how trade and biosecurity legislation impacts pharmaceutical manufacturing, see our review of the BIOSECURE act and API supply chains.
The August 2026 catalysts: Three gene therapy deaths and disclosure failures
The immediate trigger for the August 21 letter was a rapid succession of investigative reporting and corporate disclosures revealing fatal outcomes in China-based advanced-modality clinical trials that had gone unannounced to the international scientific community:
┌─────────────────────────────────────────────────────────────────────────────────────────────┐
│ AUGUST 2026 CHINA ADVANCED THERAPY FATALITY DISCLOSURES │
├─────────────────────────┬────────────────────────────┬──────────────────────────────────────┤
│ Date & Event │ Technology & Sponsor │ Regulatory & Disclosure Breakdown │
├─────────────────────────┼────────────────────────────┼──────────────────────────────────────┤
│ August 5, 2026 │ In vivo CRISPR genome │ A pediatric DMD patient died in │
│ HuidaGene Disclosure │ editing; HuidaGene │ August 2025; HuidaGene disclosed it │
│ │ Therapeutics │ only after STAT's investigation. │
├─────────────────────────┼────────────────────────────┼──────────────────────────────────────┤
│ July 23, 2026 │ Gene Therapy │ Science (with Retraction Watch) │
│ Nature Paper Omission │ Investigator-Initiated │ revealed a child's fatal outcome │
│ │ Trial (IIT) │ was omitted from a Nature paper. │
├─────────────────────────┼────────────────────────────┼──────────────────────────────────────┤
│ August 18, 2026 │ In Vivo CAR-T (RiboX │ Endpoints News reported a third │
│ CAR-T Fatality │ Therapeutics IIT) │ fatality: a systemic sclerosis │
│ │ │ patient in a company-run IIT. │
└─────────────────────────┴────────────────────────────┴──────────────────────────────────────┘
1. Investigator-Initiated Trials (IIT) Regulatory Gaps
Under China's historical regulatory framework, academic and hospital-based clinicians could conduct investigator-initiated trials (IITs) under local hospital institutional review board (IRB) ethics approvals without formal Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA). This "fast-track" pathway allowed early in-human proof-of-concept testing with minimal regulatory friction, attracting global biopharma partnerships.
2. The International Backlash
The disclosure that serious adverse events and patient deaths in IIT protocols were withheld from international registries and peer-reviewed journals created fierce criticism from U.S. lawmakers. As reported by Endpoints News, Moolenaar and Cline wrote that accepting Chinese clinical data poses "real risks for patients" and that "the offshoring of early-stage clinical trials to China risks rewarding a system that has shown it is willing to treat children's deaths as an acceptable cost of faster, cheaper research."
In response to international scrutiny, China's NMPA has moved to tighten domestic IIT oversight, mandating strict GMP compliance across hospital laboratories. For context on China's domestic regulatory rules, see our analysis of China trial data protection rules.
Current FDA authority vs congressional asks: 21 CFR 312.120 and 314.106
To evaluate whether FDA could—or will—implement an audit gate, regulatory counsel must examine the agency's governing statutory and regulatory framework for foreign clinical data.
┌─────────────────────────────────────────────────────────────────────────────────────────────┐
│ REGULATORY FRAMEWORK FOR ACCEPTING FOREIGN CLINICAL DATA │
├──────────────────────┬──────────────────────────────────────────────────────────────────────┤
│ Regulation │ Core Legal Standard & Acceptance Criteria │
├──────────────────────┼──────────────────────────────────────────────────────────────────────┤
│ 21 CFR 312.120 │ FOREIGN CLINICAL STUDIES NOT CONDUCTED UNDER A U.S. IND │
│ │ FDA accepts foreign non-IND studies if: │
│ │ 1. The study was conducted in accordance with Good Clinical Practice │
│ │ (GCP), including independent ethics committee (IEC) review; │
│ │ 2. FDA is able to validate the data through an on-site inspection if │
│ │ deemed necessary; and │
│ │ 3. The data are scientifically valid and applicable to the U.S. │
│ │ population and U.S. medical practice. │
├──────────────────────┼──────────────────────────────────────────────────────────────────────┤
│ 21 CFR 314.106 │ FOREIGN DATA AS SOLE BASIS FOR DRUG APPROVAL │
│ │ An NDA or BLA may be approved solely on foreign clinical data if: │
│ │ 1. The foreign data are applicable to the U.S. population; │
│ │ 2. The studies were performed by clinical investigators of recognized│
│ │ competence; and │
│ │ 3. The data may be considered valid without the need for an on-site │
│ │ inspection by FDA, OR if FDA considers such inspection necessary, │
│ │ FDA is able to validate the data through on-site inspection. │
└──────────────────────┴──────────────────────────────────────────────────────────────────────┘
1. "Able to Validate" vs "Must Have Audited"
Under current law (21 CFR 312.120(a)(1)(ii) and 314.106(b)(3)), FDA's statutory standard requires that the agency be "able to validate the data through an on-site inspection if the agency deems it necessary."
It does not mandate that FDA must inspect 100% of foreign clinical investigation sites prior to application filing or approval. If Congress mandates a mandatory pre-approval inspection for every Chinese trial site, it would convert an agency discretion into a rigid statutory barrier.
2. The BIMO Inspection Toolkit and Classification System
When FDA's Bioresearch Monitoring (BIMO) program audits a clinical trial site, investigators evaluate source document verification (SDV), protocol adherence, informed consent integrity, drug accountability logs, and adverse event reporting timeliness. Inspections conclude with one of three official classifications:
- NAI (No Action Indicated): No objectionable conditions found.
- VAI (Voluntary Action Indicated): Minor deviations identified, not compromising data integrity or subject safety.
- OAI (Official Action Indicated): Serious regulatory violations requiring formal regulatory sanctions, disqualification of investigators, or rejection of study data from marketing dossiers.
Precedents in foreign data reliance: Loqtorzi vs Sintilimab
FDA has established distinct, well-documented precedents regarding reliance on China-only pivotal clinical data:
┌─────────────────────────────────────────────────────────────────────────────────────────────┐
│ TALE OF TWO PRECEDENTS: LOQTORZI VS SINTILIMAB │
├──────────────────────┬──────────────────────────────────┬───────────────────────────────────┤
│ Dimension │ Loqtorzi (toripalimab-tpzi) │ Sintilimab (Tyvyt / ORIENT-11) │
├──────────────────────┼──────────────────────────────────┼───────────────────────────────────┤
│ Sponsors │ Coherus BioSciences / Junshi │ Eli Lilly / Innovent Biologics │
├──────────────────────┼──────────────────────────────────┼───────────────────────────────────┤
│ Target Indication │ Nasopharyngeal Carcinoma (NPC) │ First-line non-squamous NSCLC │
├──────────────────────┼──────────────────────────────────┼───────────────────────────────────┤
│ Pivotal Trial Scope │ JUPITER-02 & POLARIS-02: all- │ ORIENT-11 trial conducted │
│ & Geography │ Asia sites (mainland China, │ exclusively in China │
│ │ Taiwan, Singapore); no U.S. sites │ │
├──────────────────────┼──────────────────────────────────┼───────────────────────────────────┤
│ FDA Regulatory │ APPROVED (October 2023) │ REJECTED / CRL (March 2022) │
│ Outcome │ Breakthrough Therapy designation │ ODAC voted 14–1 against approval │
├──────────────────────┼──────────────────────────────────┼───────────────────────────────────┤
│ Regulatory Rationale │ Rare disease in the U.S.; high │ Common disease in the U.S. with │
│ for Decision │ unmet need; no FDA-approved │ multiple approved checkpoint │
│ │ therapies; data applicable to │ inhibitors; lacked U.S. diversity │
│ │ U.S. practice │ │
└──────────────────────┴──────────────────────────────────┴───────────────────────────────────┘
1. The Loqtorzi Precedent: Unmet Rare Disease Need
In October 2023, FDA approved Loqtorzi (toripalimab-tpzi) for advanced nasopharyngeal carcinoma (NPC) on pivotal Phase 2/3 trials (JUPITER-02 and POLARIS-02) conducted entirely in Asia — predominantly at mainland Chinese centers, with JUPITER-02 also including sites in Taiwan and Singapore and no U.S. sites at all. FDA accepted the dataset because NPC is a rare malignancy in the United States with no FDA-approved front-line systemic therapies and the disease and trial conduct were judged applicable to U.S. practice.
2. The Sintilimab Rejection: Common Disease and Population Diversity
In contrast, in February 2022, FDA's Oncologic Drugs Advisory Committee (ODAC) voted 14 to 1 against approving sintilimab for non-small cell lung cancer (NSCLC). FDA's Oncology Center of Excellence (led by Dr. Richard Pazdur) established that for common malignancies with multiple established U.S. standard-of-care therapies, foreign clinical trials must be multiregional (MRCT), reflect U.S. standard medical practice, and enroll diverse racial and ethnic populations representative of U.S. patients.
3. Bridging Strategies: Carvykti and Ivonescimab
Between Loqtorzi and sintilimab lies the multiregional bridging model:
- Carvykti (ciltacabtagene autoleucel): Legend Biotech originated the CAR-T candidate in China (LEGEND-2 study), then partnered with Johnson & Johnson (Janssen) to run the registration-directed CARTITUDE-1 study at U.S.-led sites (17 U.S. centers plus 4 in Japan), supporting the 2022 U.S. approval rather than filing directly on the Chinese data.
- Ivonescimab (AK112 / SMT112): Akeso's China-only HARMONi-A Phase 3 is being tested ex-China by Summit Therapeutics: HARMONi runs the same EGFR-mutant setting at U.S., Canadian, and European sites (no China sites), while HARMONi-3 tests a different, first-line setting against pembrolizumab.
For live monitoring of pending China-originated oncology dossiers, see our analysis of the ivonescimab FDA action date.
The operational bottleneck: What an FDA audit gate would actually do
If FDA were to adopt an audit-gate policy—or if Congress mandates it via appropriations riders—it would create a near-total operational freeze on China-reliant development programs.
WHY AN AUDIT GATE BECOMES A DE FACTO MORATORIUM
┌────────────────────────────────────────────────────────┐
│ 1. FDA BIMO INSPECTORATE CAPACITY CONSTRAINTS │
│ FDA classifies ~1,075 BIMO inspections/year │
│ (FY2023–FY2024 official metrics); foreign │
│ inspections are a small, resource-limited share. │
└───────────────────────────┬────────────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ 2. DIPLOMATIC & SOVEREIGN ACCESS FRICTION │
│ PRC visa delays, State Secrets Law compliance, │
│ and Ministry of Foreign Affairs clearances. │
└───────────────────────────┬────────────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ 3. MASSIVE REVIEW BACKLOG & FILING FREEZE │
│ Sponsors face 12–24 month delays waiting for BIMO │
│ inspections before NDAs/BLAs can be accepted. │
└────────────────────────────────────────────────────────┘
1. BIMO Resource Limitations
FDA's Bioresearch Monitoring (BIMO) program operates with a finite cadre of field investigators responsible for auditing domestic and international clinical sites, IRBs, and sponsors. Mandating on-site audits for hundreds of Chinese trial sites across multiple hospital centers would completely overwhelm agency inspection resources.
2. Geopolitical and Visa Access Friction
Conducting foreign regulatory inspections requires sovereign host-nation cooperation. In China, FDA inspectors face prolonged visa processing timelines, stringent security reviews, and potential conflicts with China's Data Security Law and Anti-Espionage Law regarding the inspection of medical records and hospital IT systems.
3. Duplicative Clinical Trial Costs
Biotechnology industry leaders (as highlighted in Fierce Biotech) caution that the shifting political landscape itself is becoming, in the words of one venture investor, "a huge distraction and a huge expense" — sponsors are already re-routing early-phase work to Australia, Japan, Singapore, and Europe as blacklist risk and congressional scrutiny complicate China siting. The practical draw of China remains speed: committee background materials note patient enrollment there runs roughly three to five times faster than U.S. recruitment, and HHS's Phase 1 pilot pathway claims to save six to 12 months.
Decision rules for Clinical Operations and Regulatory Heads
Sponsors evaluating Chinese clinical sites must establish clear operational decision boundaries:
┌─────────────────────────────────────────────────────────────────────────────────────────────┐
│ DECISION MATRIX FOR SPONSORS EVALUATING CHINA TRIAL SITES │
├──────────────────────┬──────────────────────┬──────────────────────┬────────────────────────┤
│ Clinical Stage / Type│ China Site Ratio │ Regulatory Strategy │ Critical Action Item │
├──────────────────────┼──────────────────────┼──────────────────────┼────────────────────────┤
│ Early Proof-of- │ Up to 100% of cohort │ Non-registrational; │ Ensure full informed │
│ Concept (Phase 1) │ permitted │ Translation to US IND│ consent, biobanking │
│ │ │ bridging protocol │ chain-of-custody logs │
├──────────────────────┼──────────────────────┼──────────────────────┼────────────────────────┤
│ Pivotal Phase 3 │ Capped at ~20–30% │ Global MRCT design │ Pre-specified subgroup │
│ (Common Disease) │ of total enrollment │ under ICH E17 │ consistency testing for│
│ │ │ framework │ US vs non-US cohorts │
├──────────────────────┼──────────────────────┼──────────────────────┼────────────────────────┤
│ Pivotal Phase 3 │ Up to 50–100% │ Requires prior FDA │ Submit Type B meeting │
│ (Ultra-Rare Disease) │ if US cases absent │ formal written agree-│ request for BIMO site │
│ │ │ ment on disease epidemiology & audit plan │
├──────────────────────┼──────────────────────┼──────────────────────┼────────────────────────┤
│ Hospital IITs │ 0% for US BLA/NDA │ Do not use IIT data │ Transition assets into │
│ (Investigator-led) │ pivotal filings │ as registration basis│ company-sponsored INDs │
└──────────────────────┴──────────────────────┴──────────────────────┴────────────────────────┘
Action plan for regulatory affairs and clinical operations teams
Biopharma sponsors managing ongoing or planned clinical studies in China should immediately execute a four-part risk-mitigation framework:
┌─────────────────────────────────────────────────────────────────────────────────────────────┐
│ CHINA TRIAL DATA RISK-MITIGATION FRAMEWORK │
├─────────────────────────┬───────────────────────────────────────────────────────────────────┤
│ Strategic Pillar │ Concrete Sponsor Operational Action │
├─────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 1. Trial Site Footprint │ Audit all active ClinicalTrials.gov and IND trial sites. Identify │
│ Exposure Audit │ and phase out any investigation sites affiliated with PLA military│
│ │ medical universities or located in scrutinized geographic zones. │
├─────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 2. Multiregional Trial │ Ensure all pivotal Phase 3 programs follow ICH E17 multiregional │
│ Design (ICH E17) │ clinical trial guidelines, capping China site enrollment at 20–30%│
│ │ and maintaining robust U.S. and European clinical center cohorts. │
├─────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 3. Independent Pre-BIMO │ Retain independent third-party GCP auditing firms to conduct mock │
│ Audit Readiness │ FDA BIMO audits of Chinese clinical investigator sites, source │
│ │ documentation, pharmacy logs, and local IRB ethics approvals. │
├─────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 4. Early Type B / C │ Request formal Type B pre-IND or Type C meetings with FDA review │
│ FDA Engagement │ divisions to align on the sufficiency and acceptability of foreign│
│ │ clinical data packages prior to completing pivotal enrollment. │
└─────────────────────────┴───────────────────────────────────────────────────────────────────┘
For teams tracking competitor clinical trial footprints, consult our guide on clinicaltrials.gov competitor landscape workflow.
Frequently Asked Questions
Is FDA currently banned from accepting Chinese clinical trial data?
No. Under current regulations (21 CFR 312.120 and 21 CFR 314.106), FDA is fully authorized to accept foreign clinical study data—including data from China—provided the trials comply with Good Clinical Practice (GCP), are scientifically valid, and can be applied to U.S. medical practice.
What is the difference between an appropriations rider and a congressional letter?
A congressional oversight letter (like the Moolenaar-Cline letter) communicates the views of lawmakers and requests agency action, but is not legally binding on FDA. In contrast, appropriations report language or statutory bill riders can legally restrict how FDA spends federal funding, effectively barring the agency from reviewing specific data packages.
Which U.S. drug was approved on pivotal data from China?
Loqtorzi (toripalimab-tpzi), developed by Junshi Biosciences and Coherus BioSciences, was approved by FDA in October 2023 for recurrent or metastatic nasopharyngeal carcinoma on pivotal Phase 2 and Phase 3 trials conducted entirely in Asia — predominantly at Chinese centers, with JUPITER-02 also including sites in Taiwan and Singapore — and no U.S. sites.
Did the 2026 China gene therapy deaths involve U.S. patients or FDA-approved drugs?
No. All three disclosed fatalities — a HuidaGene CRISPR patient (death in August 2025, disclosed August 2026), a child in a base-editing IIT whose death was omitted from a Nature paper (reported by Science in July 2026), and a systemic sclerosis patient in an in vivo CAR-T IIT (reported by Endpoints in August 2026) — occurred in China-based investigator-initiated trials of investigational therapies. None involved FDA-approved commercial drugs or U.S. study participants.
Has FDA previously restricted any China-related clinical trials?
Yes. In 2025, FDA announced regulatory policy restrictions halting clinical trial protocols that transport American patients' cellular material to laboratories in hostile nations (including China) for ex-vivo genetic modification, citing biosecurity and data privacy concerns.
Sources
- Endpoints News: Exclusive: Two GOP Lawmakers Call on FDA to Increase Scrutiny of Chinese Trial Data Following Deaths. August 21, 2026. endpoints.news.
- BioSpace: Lawmakers Urge FDA to Enact New China Policies After 3 Gene Therapy Deaths. August 21, 2026. biospace.com.
- House Select Committee on the Strategic Competition Between the United States and the CCP: Select Committee Letters to Pfizer, AbbVie, Eli Lilly, Merck, and Bristol Myers Squibb Regarding Clinical Trials in China. Official Press Release & Letters, June 30, 2026. chinaselectcommittee.house.gov.
- House Select Committee on the Strategic Competition Between the United States and the CCP: Letter Asking the FDA to Investigate Evidence of U.S. Pharmaceutical Companies Working with Chinese Military Entities. August 20, 2024. chinaselectcommittee.house.gov.
- House Select Committee on the Strategic Competition Between the United States and the CCP: Chairman Moolenaar's Opening Statement: China Is Cornering the Market on Our Medicines. Hearing Statement, March 18, 2026. chinaselectcommittee.house.gov.
- U.S. Food and Drug Administration (FDA): Code of Federal Regulations Title 21: Foreign Clinical Studies Not Conducted Under an IND (21 CFR 312.120) and Foreign Data (21 CFR 314.106). Electronic Code of Federal Regulations. ecfr.gov.
- STAT News: Child Dies in Gene-Editing Trial in China as Safety Questions Surround Investigator-Led Studies. August 5, 2026. statnews.com.
- Fierce Biotech: US Lawmakers' Focus on China Trials Risks Huge Distraction and Expense for Biopharma. August 2026. fiercebiotech.com.
